A phase 1 study of the CXCR4 antagonist plerixafor in combination with high‐dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators’ Consortium study (POE 10‐03)Todd M. Cooper, Patrick A. Brown, Amina Ahmed et al.|Pediatric Blood & Cancer|2017Cited by 73
Pharmacokinetically Guided Phase 1 Trial of the IGF-1 Receptor Antagonist RG1507 in Children with Recurrent or Refractory Solid TumorsR. Bagatell, Lia Gore, Cynthia E. Herzog et al.|Clinical Cancer Research|2010Cited by 48